OSE has a well-balanced R&D pipeline in terms of asset stage and technology. In the near term, much of the focus is on Tedopi, an off-the-shelf cancer vaccine, as it is the most advanced asset in development, and the Phase III Atalante 1 trial in NSCLC, which is ongoing, with a pre-defined step 1 patient survival assessment expected by end-Q120. Other recent news includes successful completion of the Phase I study with OSE-127 (anti-IL-7R) and the Tedopi out-licensing deal in South Korea.
13 Mar 2020
OSE Immunotherapeutics - Progress with key R&D assets
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
OSE Immunotherapeutics - Progress with key R&D assets
OSE Immunotherapeutics SA (OSE:PAR) | 0 0 0.0%
- Published:
13 Mar 2020 -
Author:
Dr Jonas Peciulis -
Pages:
7
OSE has a well-balanced R&D pipeline in terms of asset stage and technology. In the near term, much of the focus is on Tedopi, an off-the-shelf cancer vaccine, as it is the most advanced asset in development, and the Phase III Atalante 1 trial in NSCLC, which is ongoing, with a pre-defined step 1 patient survival assessment expected by end-Q120. Other recent news includes successful completion of the Phase I study with OSE-127 (anti-IL-7R) and the Tedopi out-licensing deal in South Korea.